ABBV Mar 2025 180.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

8.01

+0.81

(+11.25%)

As of 11:37AM EDT. Market open.

Loading interactive chart...

PR Newswire
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share in cash (Offer Price).
Zacks
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
Zacks
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.